Ampersand Capital Partners invests in MBO of Neomed-Labs

U.S. private equity firm Ampersand Capital Partners has invested in the management buyout of Neomed-Labs, a Laval, Québec-based provider of clinical immunology laboratory services for biologics drug development. Terms weren't disclosed. The seller was Neomed Institute. Launched in 2015, Neomed-Labs partners with pharmaceutical businesses, biotechnology companies and healthcare organizations in the development of vaccines and immunotherapies. It is led by President and CEO Benoit Bouche. Ampersand said it will support Neomed-Labs' organic and acquisition growth initiatives, which will include expansion into adjacent markets and geographies as well as continued growth in Québec.

DealsCanadaNorth AmericaBriefs